Previous 10 | Next 10 |
IVERIC bio (NASDAQ: ISEE ) initiated with Outperform rating and $15 (123% upside) price target at Cowen and Company. More news on: IVERIC bio, Inc., Matinas BioPharma Holdings, Inc., Pacira BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guide...
Pacira BioSciences (NASDAQ: PCRX ) has reported preliminary Q4 and FY 2019 net revenues. More news on: Pacira BioSciences, Inc., Healthcare stocks news, Read more ...
PARSIPPANY, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $421.0 million for 2019, a 25% increase compared with net revenue of $337.3 m...
PARSIPPANY, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 38 th Annual J.P. Morgan Healthcare Conference at 9:30 AM PT (12:30 PM ET) on Wednesday, January 15, 2020. Live audio of the event can be accessed by v...
A Phase 4 study evaluating Pacira BioSciences's ( PCRX +0.1% ) non-opioid pain med Exparel (bupivacaine liposome injectable suspension) in women undergoing Cesarean section achieved the primary endpoint of a statistically significant reduction in postsurgical opioid consumption while m...
PARSIPPANY, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that its Phase 4 study of EXPAREL ® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean section (C-section) achieved its primary endpoint with a statist...
Pacira BioSciences ( PCRX ) announces positive results from its Phase 3 PLAY study of EXPAREL (bupivacaine liposome injectable suspension) administered as a single-dose infiltration in pediatric patients undergoing spinal or cardiac surgeries. The study enrolled 98 patients. More ne...
PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc . (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from its Phase 3 PLAY study of EXPAREL ® (bupivacaine liposome injectable suspension) ...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
2024-06-13 14:15:06 ET Jefferies analyst issues BUY recommendation for PCRX on June 13, 2024 11:57AM ET. The previous analyst recommendation was Buy. PCRX was trading at $28.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-06-13 14:00:08 ET Glen Santangelo from Jefferies issued a price target of $36.00 for PCRX on 2024-06-13 11:57:00. The adjusted price target was set to $36.00. At the time of the announcement, PCRX was trading at $28.5. The overall price target consensus is at $52.33...
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will participate in an analyst-led ...